Session 13A: Pharma 4.0: Computational approaches to enhancing early-stage drug discovery and development - transformation through integrated AI expertise
Tracks
Track 1
Friday, October 24, 2025 |
12:15 PM - 1:00 PM |
Details
Artificial intelligence (AI) is transforming drug discovery by accelerating timelines, reducing costs, and improving success rates. To capture full value, computational scientists and those with traditional drug development backgrounds need to work together effectively. The two groups tend to have different skill bases, speak different scientific languages and often have different education and professional backgrounds. The challenge is to integrate AI expertise into the workflow, which requires interdisciplinary understanding, collaboration and integration between different disciplines and across sectors (academic research, biotech, pharma). Indicative of Industry 4.0, innovative leadership, aligned strategy, change management, and a culture where disruption can be adopted may also be keys to success.
This panel brings together experts in computational AI drug discovery across the sector. Our goal is to offer insights in an aspect of drug discovery where Australia needs to stay in touch with global leaders. Discussion will not only focus on how AI expertise can be aligned into successful development programs, but also how talent development, acquisition and integration are critical to translation from discovery to delivery.
Speaker
Dr. Jonathan Hall
Chief Executive Officer
Quibegen
Panellist
Milica Ng
Senior Director, Global Head of Data Science
CSL
Panellist
